Patents by Inventor Jeffrey Ciavarri

Jeffrey Ciavarri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Aryl alkynamide derivatives
    Patent number: 11912679
    Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.
    Type: Grant
    Filed: September 26, 2023
    Date of Patent: February 27, 2024
    Assignees: Astellas Pharma, Inc., Mitobridge, Inc.
    Inventors: Junko Maeda, Ikumi Kuriwaki, Kai Kitamura, Yumi Yamashita, Kenichi Kakefuda, Akio Kamikawa, Kenji Negoro, Wataru Hamaguchi, Ryushi Seo, Jeffrey Ciavarri
  • ARYL ALKYNAMIDE DERIVATIVES
    Publication number: 20240018113
    Abstract: [Problem] A compound which is useful as a STING inhibitor is provided. [Means for Solution] The present inventors have found aryl alkynamide derivatives having an inhibitory action on STING. The aryl alkynamide derivatives of the present invention have an inhibitory action on STING and can be used as an agent for treating an autoimmune disease, a neurodegenerative disease, a type I interferonopathy and/or other STING-mediated disease.
    Type: Application
    Filed: September 26, 2023
    Publication date: January 18, 2024
    Applicants: Astellas Pharma, Inc., Mitobridge, Inc.
    Inventors: Junko Maeda, Ikumi Kuriwaki, Kai Kitamura, Yumi Yamashita, Kenichi Kakefuda, Akio Kamikawa, Kenji Negoro, Wataru Hamaguchi, Ryushi Seo, Jeffrey Ciavarri
  • Sting modulator compounds, and methods of making and using
    Patent number: 11542293
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 9, 2018
    Date of Patent: January 3, 2023
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Stepan Vyskocil, Jeffrey Ciavarri, Courtney Cullis, Dylan Bradley England, Alexandra E. Gould, Paul Greenspan, Yongbo Hu, Steven Langston, Gang Li, Hirotake Mizutani, Masanori Okaniwa
  • STING MODULATOR COMPOUNDS, AND METHODS OF MAKING AND USING
    Publication number: 20210171565
    Abstract: The present disclosure provides STING modulators/agonists, and methods of synthesis and methods for using for the prophylaxis or treatment of cancer and other STING-related diseases. The present disclosure relates to a compound represented by the Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: June 10, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Stepan VYSKOCIL, Jeffrey CIAVARRI, Courtney CULLIS, Dylan Bradley ENGLAND, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Steven LANGSTON, Gang LI, Hirotake MIZUTANI, Masanori OKANIWA
  • STING MODULATOR COMPOUNDS WITH SULFAMATE LINKAGES, AND METHODS OF MAKING AND USING
    Publication number: 20210015915
    Abstract: The present disclosure provides novel compounds of Formula (I) below. Compounds of the disclosure act as STING modulators/agonists. The present disclosure further relates to methods of synthesis of compounds of Formula (I) and methods of using of compounds of Formula (I) for the prophylaxis or treatment of cancer and other STING-related diseases. The compounds have the structure represented by Formula (I): wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 21, 2021
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Jeffrey CIAVARRI, Dylan Bradley ENGLAND, Kenneth M. GIGSTAD, Alexandra E. GOULD, Paul GREENSPAN, Yongbo HU, Shi-Chung HUANG, Steven Paul LANGSTON, Hirotake MIZUTANI, Zhan SHI, Stepan VYSKOCIL, He XU
  • Phorboxazole compounds and methods of their preparation
    Publication number: 20070021479
    Abstract: Novel macrolactone compounds, their methods of preparation, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the macrolactone compounds may be useful, inter alia, for treating various cancers, inducing apoptosis in malignant cells, or inhibiting cancer cell division.
    Type: Application
    Filed: April 20, 2006
    Publication date: January 25, 2007
    Inventors: Thomas Razler, Amos Smith, Jeffrey Ciavarri, Tomoyasu Hirose, Tomoyasu Ishikawa
  • 2-(Amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
    Publication number: 20060040968
    Abstract: A heterocyclic inhibitor having the formula I, with the variables defined herein, which is useful for treating inflammatory and other physiological disorders in which PKC-theta isoform plays a role:
    Type: Application
    Filed: January 10, 2005
    Publication date: February 23, 2006
    Inventors: Paul Fleming, Zhan Shi, Brendan Chen, Jane Schmidt, John Reader, Neal Hone, Jeffrey Ciavarri